KRAS and malignant colon neoplasm: Taken together with the previous studies [31,32,33,34], the present findings suggest that the ability of reagents that interfere with PCs, particularly Furin, could potentially have therapeutic effects by regulating calcium regulators in colon cancer with KRAS or BRAF mutation.